Fluvoxamine: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
Assign pharmacological categories from List_of_CNS-active_medicines |
MDElliottMD (talk | contribs) parser-claude: Fluvoxamine MedTemplate refill, Top 300 stub upgrade |
||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Fluvoxamine (maleate) | ||
| brand | | brand = Luvox (US brand discontinued; generic widely available), Luvox CR, Faverin (other markets) | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:SSRIs|Selective serotonin reuptake inhibitor (SSRI)]], [[:Category:Antidepressants|Antidepressant]], [[:Category:Anxiolytics|Anxiolytic]] | ||
| | | uses = <vote slug="ocd-use">Obsessive-compulsive disorder (FDA; '''the first FDA-approved OCD medicine''', 1994)</vote>, <vote slug="social-anxiety-disorder-use">Social anxiety disorder (FDA, Luvox CR)</vote>, <vote slug="major-depressive-disorder-use">Major depressive disorder (off-label in US; FDA in many other markets)</vote>, <vote slug="ptsd-use">Posttraumatic stress disorder (off-label)</vote>, <vote slug="panic-disorder-use">Panic disorder (off-label)</vote>, <vote slug="covid19-outpatient-fluvoxamine-use">COVID-19 outpatient treatment (off-label; TOGETHER trial signal followed by mixed replication, sigma-1 anti-inflammatory rationale)</vote> | ||
| uses | | starting_dose = 50 mg PO at bedtime; titrate by 50 mg every 4-7 days to clinical effect. Total daily doses >100 mg divided BID. Luvox CR: 100 mg PO once daily, may titrate to 300 mg/day | ||
| starting_dose | | preparations = IR tablets 25, 50, 100 mg; Luvox CR capsules 100, 150 mg | ||
| preparations | | fda_max = 300 mg/day (IR or CR) | ||
| fda_max = | | pill_id = | ||
| routes | | routes = Oral | ||
| onset | | onset = OCD effect over 1-2 weeks initial, with full effect typically 6-12 weeks; among the slowest SSRIs for OCD response | ||
| duration | | duration = BID at higher doses (IR); once-daily (CR) | ||
| halflife | | halflife = ~15 hours (IR)<ref name="luvox-label">FDA Prescribing Information, Luvox CR (fluvoxamine maleate extended-release), Jazz Pharmaceuticals, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021519s019lbl.pdf</ref> | ||
| bioavailability = ~53% (oral)<ref name="luvox-label" /> | |||
| pregnancy = Observational signal for neonatal adaptation syndrome with third-trimester exposure (SSRI class effect).{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="luvox-label" /> | |||
| | | mechanism = <vote slug="fluvoxamine-mech-claim">Selective serotonin reuptake inhibitor with substantial additional '''sigma-1 receptor agonism''' that distinguishes it from other SSRIs. The sigma-1 activity is the proposed mechanism for the off-label COVID-19 outpatient trials and the anti-inflammatory rationale; it may also contribute to the OCD efficacy.</vote> '''Strong CYP1A2 inhibitor''' (the strongest among SSRIs at that isoenzyme), with major interactions: clozapine and theophylline exposure rises substantially; ramelteon and '''tizanidine combinations are contraindicated''' (~30-fold tizanidine exposure increase with severe hypotension reported); olanzapine, mexiletine, and caffeine all require attention. Also significant CYP2C19 and CYP3A4 inhibition. CPIC PGx guidance applies for CYP2C19<ref name="cpic-ssri">CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, 2023. https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/</ref>. | ||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category: | [[Category:SSRIs]] | ||
[[Category:Antidepressants]] | [[Category:Antidepressants]] | ||
[[Category:Anxiolytics]] | |||